ArticleMikrochimica acta2025
On exploring the potential of machine learning assisted nanoparticles enhanced laser induced breakdown spectroscopy as an initial screening tool for early breast cancer detection.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of cancer in low income countries is still a major health problem. This study discovers a novel diagnostic technique based on Nanoparticle-Enhanced Laser-Induced Breakdown Spectroscopy (NE-LIBS), which combines machine learning, nanotechnology, and laser-based elemental analysis as a potential early screening tool reported for the first time to our knowledge. We have explored that the incorporation of silver and copper oxide nanoparticles significantly enhances the intensity of emission signals of laser induced blood plasma, particularly of metallic biomarkers sodium and calcium, which have previously been known to reflect cancer-related metabolic changes. The use of advanced machine learning models to analyze these improved spectral features enables the accurate classification of cancerous and non-cancerous samples with an accuracy of nearly 95%. In low-income countries where conventional methods are still unavailable, machine learning assisted NE-LIBS has the potential to develop into a future platform that would enable scalable, reasonably priced initial clinical cancer screening when combined with machine learning.
Indexed as
Identifiers
40935949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.